SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name: Raltegravir Pediatric Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Substance/Mixture: Pharmaceutical

1.3 Details of the supplier of the safety data sheet

Company: MSD

Piercetown

A86 HD21 Dunboyne, Ireland

Telephone: 908-740-4000

E-mail address of person responsible for the SDS: EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

- Serious eye damage, Category 1: H318: Causes serious eye damage.
- Reproductive toxicity, Category 2: H361d: Suspected of damaging the unborn child.
- Specific target organ toxicity - single exposure, Category 3: H335: May cause respiratory irritation.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Signal word: Danger

Hazard pictograms:

- 

Hazard statements:

- H318: Causes serious eye damage.
- H335: May cause respiratory irritation.
- H361d: Suspected of damaging the unborn child.

Precautionary statements:

Prevention:

- P201: Obtain special instructions before use.
- P261: Avoid breathing dust.
P280  Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:
P304 + P340 + P312  IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/ doctor if you feel unwell.
P305 + P351 + P338 + P310  IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON CENTER/ doctor.
P308 + P313  IF exposed or concerned: Get medical advice/ attention.

Hazardous components which must be listed on the label:
Raltegravir

2.3 Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Contact with dust can cause mechanical irritation or drying of the skin. May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raltegravir</td>
<td>871038-72-1</td>
<td>Eye Dam. 1; H318</td>
<td>&gt;= 20 - &lt; 30</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Repr. 2; H361d</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>STOT SE 3; H335</td>
<td></td>
</tr>
</tbody>
</table>

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures
General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
Raltegravir Pediatric Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.6</td>
<td>16.03.2021</td>
<td>20369-00018</td>
<td>03.03.2021</td>
<td>09.10.2014</td>
</tr>
</tbody>
</table>

When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled: If inhaled, remove to fresh air. Get medical attention.

In case of skin contact: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.

In case of eye contact: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention immediately.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks: Causes serious eye damage. May cause respiratory irritation. Suspected of damaging the unborn child. Contact with dust can cause mechanical irritation or drying of the skin.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment: Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media: Water spray Alcohol-resistant foam Carbon dioxide (CO2) Dry chemical

Unsuitable extinguishing media: None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire- : Avoid generating dust; fine dust dispersed in air in sufficient
fighting concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.

Hazardous combustion products:
- Carbon oxides
- Nitrogen oxides (NOx)
- Fluorine compounds
- Chlorine compounds
- Sulphur oxides
- Metal oxides

5.3 Advice for firefighters

Special protective equipment for firefighters:
- In the event of fire, wear self-contained breathing apparatus.
- Use personal protective equipment.

Specific extinguishing methods:
- Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
- Use water spray to cool unopened containers.
- Remove undamaged containers from fire area if it is safe to do so.
- Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions:
- Use personal protective equipment.
- Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions:
- Avoid release to the environment.
- Prevent further leakage or spillage if safe to do so.
- Retain and dispose of contaminated wash water.
- Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up:
- Sweep up or vacuum up spillage and collect in suitable container for disposal.
- Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
- Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
- Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
- Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.
6.4 Reference to other sections
See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures: Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation: If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling: Avoid breathing dust. Do not swallow. Do not get in eyes. Avoid prolonged or repeated contact with skin. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Keep container tightly closed. Already sensitised individuals should consult their physician regarding working with respiratory irritants or sensitizers. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers: Keep in properly labelled containers. Store locked up. Keep tightly closed. Keep in a cool, well-ventilated place. Store in accordance with the particular national regulations.

Advice on common storage: Do not store with the following product types: Strong oxidizing agents

7.3 Specific end use(s)

Specific use(s): No data available
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Raltegravir Pediatric Formulation

Version 2.6  Revision Date: 16.03.2021  SDS Number: 20369-00018  Date of last issue: 03.03.2021  Date of first issue: 09.10.2014

<table>
<thead>
<tr>
<th>Substance name</th>
<th>End Use</th>
<th>Exposure routes</th>
<th>Potential health effects</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>1,2-Benzisothiazol-3(2H)-one 1,1-dioxide, sodium salt</td>
<td>Workers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>1.68 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Workers</td>
<td>Skin contact</td>
<td>Long-term systemic effects</td>
<td>0.952 mg/kg bw/day</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>0.414 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Skin contact</td>
<td>Long-term systemic effects</td>
<td>0.476 mg/kg bw/day</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Ingestion</td>
<td>Long-term systemic effects</td>
<td></td>
</tr>
</tbody>
</table>

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

<table>
<thead>
<tr>
<th>Substance name</th>
<th>Environmental Compartment</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>1,2-Benzisothiazol-3(2H)-one 1,1-dioxide, sodium salt</td>
<td>Fresh water</td>
<td>0.0158 mg/l</td>
</tr>
<tr>
<td></td>
<td>Marine water</td>
<td>0.00158 mg/l</td>
</tr>
<tr>
<td></td>
<td>Intermittent use/release</td>
<td>0.158 mg/l</td>
</tr>
</tbody>
</table>

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

8.2 Exposure controls

Engineering measures
Minimize workplace exposure concentrations.
Apply measures to prevent dust explosions.
Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).
If sufficient ventilation is unavailable, use with local exhaust ventilation.

Personal protective equipment

Eye protection : Wear the following personal protective equipment:
Chemical resistant goggles must be worn.
If splashes are likely to occur, wear:
Face-shield
Equipment should conform to I.S. EN 166

Hand protection

Material : Chemical-resistant gloves

Remarks : Choose gloves to protect hands against chemicals depending on the concentration and quantity of the hazardous substance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.

Skin and body protection : Select appropriate protective clothing based on chemical
resistance data and an assessment of the local exposure potential. Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).

Respiratory protection: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. Equipment should conform to I.S. EN 143

Filter type: Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical state</td>
<td>powder</td>
</tr>
<tr>
<td>Colour</td>
<td>yellow-orange</td>
</tr>
<tr>
<td>Odour</td>
<td>No data available</td>
</tr>
<tr>
<td>Odour Threshold</td>
<td>No data available</td>
</tr>
<tr>
<td>Melting point/freezing point</td>
<td>No data available</td>
</tr>
<tr>
<td>Initial boiling point and boiling range</td>
<td>No data available</td>
</tr>
<tr>
<td>Flammability (solid, gas)</td>
<td>May form explosive dust-air mixture during processing, handling or other means.</td>
</tr>
<tr>
<td>Flammability (liquids)</td>
<td>No data available</td>
</tr>
<tr>
<td>Upper explosion limit / Upper flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Lower explosion limit / Lower flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Flash point</td>
<td>No data available</td>
</tr>
<tr>
<td>Auto-ignition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>Decomposition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>Decomposition temperature Decomposition temper-</td>
<td>No data available</td>
</tr>
<tr>
<td>tature</td>
<td></td>
</tr>
<tr>
<td>pH</td>
<td>No data available</td>
</tr>
<tr>
<td>Viscosity</td>
<td>No data available</td>
</tr>
<tr>
<td>Viscosity, kinematic</td>
<td>No data available</td>
</tr>
<tr>
<td>Solubility(ies)</td>
<td>No data available</td>
</tr>
<tr>
<td>Water solubility</td>
<td>No data available</td>
</tr>
<tr>
<td>Partition coefficient: n-octanol/water</td>
<td>No data available</td>
</tr>
<tr>
<td>Vapour pressure</td>
<td>No data available</td>
</tr>
<tr>
<td>Relative density</td>
<td>No data available</td>
</tr>
</tbody>
</table>
Relative vapour density : No data available
Particle characteristics
  Particle size : No data available

9.2 Other information
Explosives : Not explosive
Oxidizing properties : The substance or mixture is not classified as oxidizing.
Evaporation rate : No data available
Molecular weight : No data available

SECTION 10: Stability and reactivity

10.1 Reactivity
Not classified as a reactivity hazard.

10.2 Chemical stability
Stable under normal conditions.

10.3 Possibility of hazardous reactions
Hazardous reactions : May form explosive dust-air mixture during processing, han-
dling or other means. Can react with strong oxidizing agents.

10.4 Conditions to avoid
Conditions to avoid : Heat, flames and sparks. Avoid dust formation.

10.5 Incompatible materials
Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products
No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008
Information on likely routes of exposure : Inhalation
  : Skin contact
  : Ingestion
  : Eye contact

Acute toxicity
Not classified based on available information.
Components:

Raltegravir:
Acute oral toxicity: LD50 (Mouse, male and female): > 2,000 mg/kg

Skin corrosion/irritation
Not classified based on available information.

Components:

Raltegravir:
Species: Rabbit
Result: No skin irritation

Serious eye damage/eye irritation
Causes serious eye damage.

Components:

Raltegravir:
Species: Bovine cornea
Result: Severe irritation

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Components:

Raltegravir:
Test Type: Local lymph node assay (LLNA)
Species: Mouse
Result: negative

Germ cell mutagenicity
Not classified based on available information.

Components:

Raltegravir:
Genotoxicity in vitro: Test Type: reverse mutation assay
Result: negative

Test Type: Alkaline elution assay
Test system: rat hepatocytes
Result: negative

Test Type: Chromosomal aberration
Method: OECD Test Guideline 473
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Raltegravir Pediatric Formulation

Version  2.6  Revision Date:  16.03.2021  SDS Number:  20369-00018  Date of last issue: 03.03.2021  Date of first issue: 09.10.2014

Result: negative

Genotoxicity in vivo:
Test Type: In vivo micronucleus test
Species: Mouse
Result: negative

Test Type: Chromosomal aberration
Method: OECD Test Guideline 475
Result: negative

Carcinogenicity
Not classified based on available information.

Components:

Raltegravir:
Species: Mouse, male and female
Exposure time: 104 weeks
Result: negative

Reproductive toxicity
Suspected of damaging the unborn child.

Components:

Raltegravir:
Effects on fertility:
Test Type: Fertility/early embryonic development
Species: Rat, male and female
Application Route: Oral
General Toxicity - Parent: NOAEL: 600 mg/kg body weight
Result: negative

Effects on foetal development:
Species: Rat
Application Route: Oral
General Toxicity Maternal: NOAEL: >= 600 mg/kg body weight
Teratogenicity: LOAEL F1: 300 mg/kg body weight
Symptoms: Skeletal malformations
Result: positive

Species: Rabbit
General Toxicity Maternal: NOAEL: >= 1,000 mg/kg body weight
Teratogenicity: NOAEL: >= 1,000 mg/kg body weight
Result: negative

Reproductive toxicity - Assessment
Some evidence of adverse effects on development, based on animal experiments.

STOT - single exposure
May cause respiratory irritation.
Components:

Raltegravir:
- Exposure routes: Inhalation
- Target Organs: Respiratory Tract
- Assessment: May cause respiratory irritation.

STOT - repeated exposure
Not classified based on available information.

Repeated dose toxicity

Components:

Raltegravir:
- Species: Dog
  - NOAEL: 90 mg/kg
  - Application Route: Oral
  - Exposure time: 371 d
  - Symptoms: Vomiting
- Species: Rat
  - NOAEL: 30 mg/kg
  - LOAEL: 120 mg/kg
  - Application Route: Oral
  - Exposure time: 189 d
  - Target Organs: Stomach
- Species: Mouse
  - NOAEL: 50 mg/kg
  - LOAEL: 500 mg/kg
  - Application Route: Oral
  - Exposure time: 14 Weeks
  - Target Organs: Stomach
- Species: Rat
  - NOAEL: 50 mg/kg
  - LOAEL: 200 mg/kg
  - Application Route: Oral
  - Exposure time: 8 Weeks
  - Target Organs: Stomach

Aspiration toxicity
Not classified based on available information.

11.2 Information on other hazards

Endocrine disrupting properties

Product:
- Assessment: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at
Experience with human exposure

**Components:**

**Raltegravir:**

**Ingestion:** Symptoms: Nausea, Diarrhoea, Headache, Fever, Rash, Skin irritation

**SECTION 12: Ecological information**

**12.1 Toxicity**

**Components:**

**Raltegravir:**

**Toxicity to fish**:
- LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l
  - Exposure time: 96 h
  - Method: OECD Test Guideline 203
- LC50 (Cyprinodon variegatus (sheepshead minnow)): > 100 mg/l
  - Exposure time: 96 h
  - Method: OECD Test Guideline 203

**Toxicity to daphnia and other aquatic invertebrates**:
- EC50 (Daphnia magna (Water flea)): > 100 mg/l
  - Exposure time: 48 h
  - Method: OECD Test Guideline 202

**Toxicity to algae/aquatic plants**:
- EC50 (Pseudokirchneriella subcapitata (green algae)): 66 mg/l
  - Exposure time: 96 h
  - Method: OECD Test Guideline 201
- NOEC (Pseudokirchneriella subcapitata (green algae)): 3.8 mg/l
  - Exposure time: 96 h
  - Method: OECD Test Guideline 201

**Toxicity to microorganisms**:
- EC50: > 1,000 mg/l
  - Exposure time: 3 h
  - Test Type: Respiration inhibition
  - Method: OECD Test Guideline 209
- NOEC: 1,000 mg/l
  - Exposure time: 3 h
  - Test Type: Respiration inhibition
  - Method: OECD Test Guideline 209

**Toxicity to fish (Chronic toxicity)**:
- NOEC: 9.3 mg/l
  - Exposure time: 33 d
  - Species: Pimephales promelas (fathead minnow)
  - Method: OECD Test Guideline 210
Raltegravir Pediatric Formulation

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):

- NOEC: 9.5 mg/l
- Exposure time: 21 d
- Species: Daphnia magna (Water flea)
- Method: OECD Test Guideline 211

12.2 Persistence and degradability

**Components:**

**Raltegravir:**

- Biodegradability: Result: rapidly degradable
- Biodegradation: 50%
- Exposure time: 9 d
- Method: OECD Test Guideline 302B

- Stability in water: Hydrolysis: < 10 % (5 d)
- Method: OECD Test Guideline 111

12.3 Bioaccumulative potential

**Components:**

**Raltegravir:**

- Partition coefficient: n-octanol/water: log Pow: -0.328

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment

**Product:**

- Assessment: This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Endocrine disrupting properties

**Product:**

- Assessment: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

12.7 Other adverse effects

No data available

**SECTION 13: Disposal considerations**

13.1 Waste treatment methods
SECTION 14: Transport information

14.1 UN number or ID number
Not regulated as a dangerous good

14.2 UN proper shipping name
Not regulated as a dangerous good

14.3 Transport hazard class(es)
Not regulated as a dangerous good

14.4 Packing group
Not regulated as a dangerous good

14.5 Environmental hazards
Not regulated as a dangerous good

14.6 Special precautions for user
Not applicable

14.7 Maritime transport in bulk according to IMO instruments
Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII) : Not applicable

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59). : Not applicable

REACH - List of substances subject to authorisation (Annex XIV) : Not applicable

Regulation (EC) No 1005/2009 on substances that deplete the ozone layer : Not applicable

Regulation (EU) 2019/1021 on persistent organic pollutants (recast) : Not applicable

Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals : Not applicable

SAFETY DATA SHEET according to Regulation (EC) No. 1907/2006

Raltegravir Pediatric Formulation

Version 2.6 Revision Date: 16.03.2021 SDS Number: 20369-00018 Date of last issue: 03.03.2021 Date of first issue: 09.10.2014

Other regulations:
Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.

The components of this product are reported in the following inventories:
AICS : not determined
DSL : not determined
IECSC : not determined

15.2 Chemical safety assessment
A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements
H318 : Causes serious eye damage.
H335 : May cause respiratory irritation.
H361d : Suspected of damaging the unborn child.

Full text of other abbreviations
Eye Dam. : Serious eye damage
Repr. : Reproductive toxicity
STOT SE : Specific target organ toxicity - single exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Raltegravir Pediatric Formulation

Version   Revision Date:   SDS Number:   Date of last issue: 03.03.2021
2.6        16.03.2021     20369-00018   Date of first issue: 09.10.2014

Sources of key data used to compile the Safety Data Sheet:

Classification of the mixture:
- Eye Dam. 1: H318 - Calculation method
- Repr. 2: H361d - Calculation method
- STOT SE 3: H335 - Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

IE / EN